CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water

Xenobiotica

Volumn 35, Issue 5, 2005, Pages 519-530

  Adonis, M ^a   Martinez V ^a   Marin P ^b   Gil, L ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Hospital Regional de Antofagasta   (Chile)

Author keywords

Arsenic; Lung cancer; Polymorphism; Susceptibility biomarkers

Indexed keywords

ARSENIC; COPPER; CYTOCHROME P450 1A1; DRINKING WATER; GLUTATHIONE; GLUTATHIONE TRANSFERASE M1;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CHILE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MINING; POLYMERASE CHAIN REACTION; POPULATION EXPOSURE; SMOKING HABIT; STATISTICAL ANALYSIS; VOLUNTEER; WATER CONTAMINATION;

EID: 22944459513     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500057310     Document Type: Article

References (49)

1. Abbas A, Delvinquiere K, Lechevrel M, Lebailly P, Gauduchon P, Launoy G, Sichel F. 2004. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World Journal of Gastroenterology 10:3389-3393.
2. Adonis M, Gil L. 2000. Polycyclic aromatic hydrocarbons levels and mutagenicity of inhalable particulate matter in Santiago, Chile. Inhalation Toxicology 12:1173-1183.
3. Adonis M, Gil L. 2001. Indoor air pollution in a zone of extreme poverty area of metropolitan Santiago. Indoor and Built Environment 10:138-146.
4. Adonis M, Riquelme R, Ríos C, Rodríguez L, Rodríguez E, Martínez V, Gil L. 2003. PAHs and mutagenicity of inhalable and respirable particulate matter from diesel exhaust in Santiago, Chile. Polycyclic Aromatic Compounds 23:495-514.
5. Ambrosone C, Freudenheim J, Oraham S, Marshall J, Vena J, Brasure J, Laughlin R, Nemoto T, Michalek A, Harrington A, Ford T, Shields P. 1995. Cytochrome P4501A1 and glutathione S-transferase (MI) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Research 55:3483-3485.
6. ATSDR. 2000 (available at: http://www.atsdr.cdc.gov/cgi-bin/search).
7. Attia J, Thakkinstian A, D'Este C. 2003. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. Journal of Clinical Epidemiology 56:297-303.
8. Byrd DM, Roegner ML, Griffiths JC, Lamm SH, Grumski KS, Wilson R, Lai S. 1996. Carcinogenic risks of inorganic arsenic in perspective. International Archives of Occupational and Environmental Health 68:484-494.
9. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. 1996. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arteriosclerosis, Thrombosis and Vascular Biology 16:504-510.
10. Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, Wei ML, Chen HC, Yang HT, Leu LC, Chu TH, Chen-Wu C, Yang MH, Chen CJ. 1997. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutation Research 386:197-207.
11. Daly AK, Cholerton S, Armstrong M, Idle JR. 1994. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environmental Health Perspectives 102 (Suppl. 9): 55-61.
12. De Gregori I, Fuentes E, Rojas M, Pinochet H, Potin-Gautier M. 2003. Monitoring of copper, arsenic and antimony levels in agricultural soils impacted and non-impacted by mining activities, from three regions in Chile. Environmental Monitoring 5:287-295.
13. Ding L, Ping S, Jingmei Y. 1999. Application of tumor marker of DR-70 in the diagnosis of malignant tumors. Chongqing Medical Journal 28(5).
14. Ferreccio C, Gonzalez C, Milosavjlevic V, Marshall G, Sancha AM, Smith AH. 2001. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 12:283.
15. Germolec D, Spalding J, Yu H, Chen G, Simeonova P, Humble M, Bruccoleri A, Boorman G, Foley J, Yoshida T, Luster M. 1998. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. American Journal of Pathology 153:1775-1785.
16. Gil L, King L, Adonis M. 2000. Trends of polycyclic aromatic hydrocarbons levels and mutagenicity in Santiago's inhalable airborne particles in the period 1992-1996. Inhalation Toxicology 12:1185-1204.
17. Gil L, Martínez V, Riquelme R, Ancic P, González G, Rodríguez L, Adonis M. 2003. Occupational and environmental levels of mutagenic PAHs and respirable particulate matter associated with diesel exhaust in Santiago. Chile Journal of Occupational and Environmental Medicine 45:984-992.
18. Goering PL, Aposhian HV, Mass MJ, Cebrian M, Beck BD, Waalkes MP. 1999. The enigma of arsenic carcinogenesis: role of metabolism. Toxicology Science 49:5-14.
19. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. 1991. PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acid Research 19:47-97.
20. Huff J, Chan P, Nyska A. 2000. Is the human carcinogen arsenic carcinogenic to laboratory animals? Toxicology Science 55:17-23.
21. INE (available at: http://www.ine.cl).
22. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M. 2004. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatric Blood Cancer 43:560-567.
23. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW. 2000. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. Journal of Biological Chemistry 275:33404-33408.
24. Leslie EM, Haimeur A, Waalkes MP. 2004. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. Journal of Biological Chemistry 279:32700-32708.
25. London SJ, Smart J, Daly AK. 2000. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 28:147-155.
26. Lovell MA, Farmer JG. 1985. Arsenic speciation in urine from humans intoxicated by inorganic arsenic compounds. Human Toxicology 4:203-214.
27. Mazumder DN, Haque R, Ghosh N, De BK, Santra A, Chakraborti D, Smith AH. 2000. Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. International Journal of Epidemiology 29:1047-1052.
28. Medina E, Kaempffer AM. 2001. Mortalidad por cancer en Chile: consideraciones epidemiológicas. Revista Médica de Chile 19:1-11.
29. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 16:1215.
30. 2.5): relationships between indoor, outdoor and personal concentrations. Science of the Total Environment 3:15-21.
31. Moore MM, Harrington-Brock K, Doerr CL. 1997. Relative genotoxic potency of arsenic and its methylated metabolites. Mutation Research 386:279-290.
32. Pott WA, Benjamin SA, Yang RS. 2001. Pharmacokinetics, metabolism, and carcinogenicity of arsenic. Reviews in Environmental Contamination and Toxicology 169:165-214.
33. Queirolo F, Stegen S, Mondaca J, Cortes R, Rojas R, Contreras C, Munoz L, Schwuger MJ, Ostapczuk P. 2000. Total arsenic, lead, cadmium, copper, and zinc in some salt rivers in the northern Andes of Antofagasta, Chile. Science of the Total Environment 255:85-95.
34. Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, Lee K, Acevedo C, Martínez L, Aguilera AM, Gil L. 2001. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Letters 174:35-44.
35. Radabaugh TR, Aposhian HV. 2000. Enzymatic reduction of arsenic compounds in mammalian systems: reduction of arsenate to arsenite by human liver arsenate reductase. Chemical Research in Toxicology 13:26-30.
36. Radabaugh TR, Sampayo-Reyes A, Zakharyan RA, Aposhian HV. 2002. Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chemical Research in Toxicology 15:692-698.
37. Rivara MI, Cebrián M, Corey G, Hernandez M, Romieu I. 1997. Cancer risk in an arsenic contaminated area of Chile. Toxicology and Industrial Health 13:321-338.
38. Rossman T. 1998. Arsenic. In: Rom WN, editor. Environmental and occupational medicine. Philadelphia: Lippencott Raven, p. 1011-1019.
39. Slattery ML, Samowtiz W, Ma K, Murtaugh M, Sweeney C, Levin TR, Neuhausen S. 2004. CYP1A1, cigarette smoking, and colon and rectal cancer. American Journal of Epidemiology 160:842-852.
40. Smith AH, Goycolea M, Haque R, Biggs ML. 1998. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. American Journal of Epidemiology 147:660-669.
41. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Archives in Toxicology 74:289-299.
42. Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. 2004. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. Journal of Bone and Mineral Research 19:419-428.
43. Thomas DJ, Styblo M, Lin S. 2001. The cellular metabolism and systemic toxicity of arsenic. Toxicology and Applied Pharmacology 176:127-144.
44. Vahter M. 1999. Methylation of inorganic arsenic in different mammalian species and population groups. Science Progress 82:69-88.
45. Vahter M. 2002. Mechanisms of arsenic biotransformation. Toxicology 181-182:211-217.
46. Waalkes MP, Ward JM, Liu J, Diwan BA. 2003. Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicology and Applied Pharmacology 186:7-17.
47. Wu D, Zhou X, Yang G, Xie Y, Hu M, Wu Z, Yang G, Lu M. 1998. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. Journal of Immunoassay 19:63-72.
48. Yang XR, Wacholder S, Xu Z, Dean M, Clark V, Gold B, Brown LM, Stone BJ, Fraumeni JF Jr, Caporaso NE. 2004. CYP1A1 and GSTM1 polymorphisms in relation to lung cancer risk in Chinese women. Cancer Letters 214:197-204.
49. Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, Aposhian HV. 2001. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chemical Research in Toxicology 14:1051-1057.